Skip to main content

Clinical Trials

The Canadian Cancer Trials Group (CCTG) supports national and international multicentre phase I-III cancer clinical research trials aimed at improving the survival and quality of life of cancer patients across all cancer types. The scientific agenda for the group is developed by clinical researchers across Canada and beyond, includes trials of new cancer agents, novel radiation and surgical techniques, as well as interventions to improve patient quality of life.

If you are a CCTG member and need to access the full trials pages please click here.

The links below will take you to pages that list all the current CCTG trials with a brief description. If you are interested in volunteering for a trial we suggest that you discuss the opportunity with your care team.

If you are a patient or caregiver and are looking for other information about clinical trials a complete listing of clinical trials being conducted in Canada, including the locations where they are being conducted, can be found here: Canadian Cancer Trials.  And if you are interested in learning about participating in a clinical trial more information can be found here: www.itstartswithme.ca

 

How can I participate in a clinical trial

 

How can I participate in a clinical trial

CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost)

CCTG PR24 trial opens to investigate Stereotactic Ablative Body Radiotherapy effectiveness in treating prostate cancer

Now open the CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost) for men with unfavourable risk prostate cancer. SBRT is a non-invasive, high precision, less costly radiation technique that results in similar outcomes and tolerability to brachytherapy boost.

More >>
 
CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.

More >>
 
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial

CIHR has announces funding for the TACtful cell therapy trial

CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.

More >>
 
CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement

CCTG NE2 trial successfully funded by CIHR

​The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.

More >>